The hemorrhoid treatment market addresses both mild and severe anal vein disorders through over-the-counter (OTC) creams, ointments, and minimally invasive procedures like rubber band ligation, sclerotherapy, and infrared coagulation. Growth is driven by the high prevalence of hemorrhoids—particularly among the elderly and those with sedentary lifestyles—and rising consumer awareness. OTC product availability and convenient access via pharmacies and online platforms have also contributed to market expansion. Ongoing innovations, including faster-acting formulations and advanced minimally invasive devices, support broader adoption. As stigma around the condition decreases and treatment-seeking rises, the market is well-positioned for steady global growth.
According to Fortune Business Insights, the global hemorrhoid treatment market was valued at USD 1.03 billion in 2023. The market is projected to grow from USD 1.08 billion in 2024 to USD 1.74 billion by 2032, exhibiting a CAGR of 6.1% during the forecast period. In 2023, North America dominated the hemorrhoid treatment market with a market share of 44.66%.
In September 2024, Haleon Group agreed to acquire Tianjin TSKF Pharmaceutical Co. Ltd. in China to enhance strategic and operational control, strengthening its position in the hemorrhoid treatment market.
Growing Disease Prevalence: Hemorrhoids affect an estimated 4.4% of the global population, with higher rates among the elderly . Risk factors such as sedentary lifestyles, obesity, and chronic constipation have driven an increasing need for both OTC and prescription treatments.
Availability of OTC Treatments: Over-the-counter hemorrhoid drugs—widely available in pharmacies and online—have fueled market growth. Notably, in March 2024, Karo Healthcare obtained exclusive rights to market Proctosedyl OTC in Italy, demonstrating how OTC access enhances regional adoption .